ALECSAT

Results: 1



#Item
1VAXIMM initiates Phase 1 translational study in glioblastoma with oral T-cell immunotherapy, VXM01 Basel (Switzerland) and Mannheim (Germany), July 12, 2016 – VAXIMM AG, a Swiss/German biotech company focused on develo

VAXIMM initiates Phase 1 translational study in glioblastoma with oral T-cell immunotherapy, VXM01 Basel (Switzerland) and Mannheim (Germany), July 12, 2016 – VAXIMM AG, a Swiss/German biotech company focused on develo

Add to Reading List

Source URL: sunstone.eu

Language: English - Date: 2016-07-12 04:22:18